Skip to main content

Table 1 Basic characteristics and NGS examination of four patients

From: Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

  Patient 1 Patient 2 Patient 3 Patient 4
Age 62 60 59 67
Gender male female female male
Race Asian Asian Asian Asian
TNM stage IV IV IV IIIB
Pathology Moderately differentiated adenocarcinoma Invasive adenocarcinoma Poorly differentiated adenocarcinoma Invasive adenocarcinoma
EGFR-TKIs Gefitinib Gefitinib Gefitinib Gefitinib
Regimen 250 mg, qd 250 mg, qd 250 mg, qd 250 mg, qd
PFS (months) 5.2 6.9 8.1 5.1
Genomic alterations EGFR Exon 21 L858R
MDM2 Amplification
TP53 D208G
ERBB4 L770V
BLM D997N
EGFR Exon 19 Deletion
MDM2 Amplification
CDK4 Amplification
ARID1B Q1312K
NKX2–1 G115S
PTCH1 G1136
RET R475W
EGFR Exon 19 Deletion
MDM2 Amplification
EGFR Amplification
CDK4 Amplification
CTIF R77L
APC L1564
EGFR Exon 21 L858R
MDM2 Amplification
FLT3 P336T
FYN L411M
FANCL M89I
NCOR1 P347T